Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...

Eli Lilly & Co. Inc.’s stock rose 2.3% Wednesday ... The trial enrolled 751 participants across the U.S. and Puerto Rico. “Given the increased interest around obesity medications, we conducted ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.